Browse by Poster Presenter

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

E
Ebata, Kevin

Loxo@Lilly
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Kevin Ebata
Favorite
Edmond, Bruno

Analysis Group, Inc.
2025 - Real-world dosing patterns and outcomes in patients with chronic lymphocytic leukemia patients with or without dose adjustment of first-line ibrutinib
Bruno Edmond
Favorite
Edwards, Kurtis

University of Westminster
1021 - Transcriptional correlation analysis of the CD180/MD-1 complex and toll-like receptors and signaling lymphocyte activation family receptors in chronic lymphocytic leukemia.
Kurtis Edwards
Favorite
Eek, Richard

Bendigo Medical Oncology
1218 - Lenalidomide Consolidation Improves Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
Richard Eek
Favorite
Efremov, Dimitar G.

International Centre for Genetic Engineering and Biotechnology
1038 - Inhibition of G protein-coupled receptor kinase 2 (GRK2) as a strategy to modulate leukemic cell homing and activation in CLL
Dimitar G. Efremov
Favorite
Egle, Alexander

3rd Medical Dept. with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Alexander Egle
Favorite
Eichhorst, Barbara

Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Barbara Eichhorst
Favorite
1212 - Targeted agents in chronic lymphocytic leukemia (CLL): Data on outcomes and subsequent therapies of patients observed within the German CLL Study Group (GCLLSG) registry
Barbara Eichhorst
Favorite
2002 - Final 7-year Follow Up and Retreatment Substudy Analysis of MURANO: Venetoclax-Rituximab-Treated Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Barbara Eichhorst
Favorite
2013 - Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Barbara Eichhorst
Favorite
2014 - Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Barbara Eichhorst
Favorite
2017 - Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study
Barbara Eichhorst
Favorite
Ekström, Nina

Department of Health Security, Finnish Institute for Health and Welfare
1154 - Impaired long-term antibody persistence after primary immunization with pneumococcal vaccines in patients with chronic lymphocytic leukemia compared to immunocompetent controls
Nina Ekström
Favorite
Eldering, Eric

1 Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam institute for Infection and Immunity
1044 - T cells from chronic lymphocytic leukemia patients are not exhausted but show signs of senescence, providing alternative clues for improvement
Eric Eldering
Favorite
Eldering, Eric F.

Amsterdam University Medical Centers
1024 - Impaired mitochondrial metabolism drives T-cell dysfunction in chronic lymphocytic leukemia
Eric F. Eldering
Favorite
Eliason, Laurie

Bristol Myers Squibb
2021 - Health-related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso-cel in TRANSCEND CLL 004
Laurie Eliason
Favorite
Elliott, Michael

University of Virginia
1138 - Low dose rituximab efficiently clears circulating CLL cells and maintains sensitivity to antibody dependent cellular cytotoxicity (ADCP)
Michael Elliott
Favorite
1139 - Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10
Michael Elliott
Favorite
El-Sharkawi, Dima

Royal Marsden NHS Foundation Trust
3008 - An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)
Dima El-Sharkawi
Favorite
Emechebe, Nnadozie

AbbVie
1143 - The Economic Benefits of Time Off Treatment: Real-World HRU, Costs, and Subsequent Treatment with Fixed Duration Venetoclax among Patients with Chronic Lymphocytic Leukemia
Nnadozie Emechebe
Favorite
1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Nnadozie Emechebe
Favorite
Enserink, Jorrit

Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital
1135 - Predictive modeling of treatment outcomes in chronic lymphocytic leukemia based on functional profiles at baseline
Jorrit Enserink
Favorite
Epstein-Peterson, Zachary

Memorial Sloan Kettering Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Zachary Epstein-Peterson
Favorite
Eradat, Herbert

David Geffen School of Medicine at UCLA
3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Herbert Eradat
Favorite
Erba, Harry

Duke
3007 - Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab (VO) versus Delayed Therapy with VO in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study (SWOG S1925; NCT#04269902)
Harry Erba
Favorite
Escalón, Maricer

Eli Lilly and Company
2008 - BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
Maricer Escalón
Favorite
Espinet, Blanca

Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain/Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain
1152 - Optical genome mapping and fluorescence in situ hybridization is the best combination to identify genomic complexity and TP53 deletions in CLL patients
Blanca Espinet
Favorite
Eyre, Toby A.

Churchill Cancer Center, Oxford University Hospitals NHS Foundation Trust
1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Toby A. Eyre
Favorite
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Toby A. Eyre
Favorite
2011 - Long-term Safety with ≥12 Months of Pirtobrutinib in Relapsed/Refractory (R/R) B-Cell Malignancies
Toby A. Eyre
Favorite
2012 - Matching-Adjusted Indirect Comparison of Pirtobrutinib vs Venetoclax Continuous Monotherapy in Patients with Relapsed/Refractory CLL Previously Treated with a Covalent BTK Inhibitor
Toby A. Eyre
Favorite
3001 - Sequencing of circulating tumour DNA reveals additional driver mutations in Richter Transformation
Toby A. Eyre
Favorite
3005 - BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
Toby A. Eyre
Favorite